Telomir Pharmaceuticals, Inc. (TELO)

Focuses on developing therapies targeting telomeres for cancer and age-related diseases.

TELO Stock Quote

Company Report

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company headquartered in Baltimore, Maryland, specializing in the development and commercialization of therapeutic treatments targeting human stem cells. The company's primary focus is on advancing TELOMIR-1, an innovative small molecule designed to serve as an oral therapeutic intervention for age-related inflammatory conditions. These conditions include hemochromatosis and osteoarthritis, as well as addressing health issues that may arise post-chemotherapy.

Formerly known as Metallo Therapies Inc., Telomir Pharmaceuticals underwent a name change in October 2022 to reflect its renewed focus and strategic direction in pharmaceutical innovation. Since its incorporation in 2021, the company has rapidly positioned itself as a key player in the field of therapeutic treatments for stem cell-related disorders.

Telomir Pharmaceuticals is committed to leveraging cutting-edge research and development to advance TELOMIR-1 and expand its pipeline of novel therapies. With a mission to address unmet medical needs through innovative science, the company aims to improve patient outcomes and enhance quality of life for individuals affected by these debilitating conditions.

TELO EPS Chart

TELO Revenue Chart

Stock Research

ARVN CMTL OCAX ALGT DLNG PKOH LE

TELO Chart

View interactive chart for TELO

TELO Profile

TELO News

Analyst Ratings